JPH0517367A - 骨粗鬆症治療剤 - Google Patents

骨粗鬆症治療剤

Info

Publication number
JPH0517367A
JPH0517367A JP3192714A JP19271491A JPH0517367A JP H0517367 A JPH0517367 A JP H0517367A JP 3192714 A JP3192714 A JP 3192714A JP 19271491 A JP19271491 A JP 19271491A JP H0517367 A JPH0517367 A JP H0517367A
Authority
JP
Japan
Prior art keywords
csf
injection
group
osteoporosis
treating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3192714A
Other languages
English (en)
Japanese (ja)
Inventor
Takuji Hanamura
卓司 花村
Ryoko Ri
良子 李
Yasushi Matsuoka
靖史 松岡
Masanori Sugiura
杉浦　　正典
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Mitsubishi Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp Japan
Morinaga Milk Industry Co Ltd
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp Japan, Morinaga Milk Industry Co Ltd, Green Cross Corp Korea filed Critical Green Cross Corp Japan
Priority to JP3192714A priority Critical patent/JPH0517367A/ja
Priority to PCT/JP1992/000874 priority patent/WO1993000921A1/ja
Priority to CA002090453A priority patent/CA2090453A1/en
Priority to EP92914092A priority patent/EP0547234A1/en
Priority to KR1019930700665A priority patent/KR930702016A/ko
Publication of JPH0517367A publication Critical patent/JPH0517367A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP3192714A 1991-07-08 1991-07-08 骨粗鬆症治療剤 Pending JPH0517367A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP3192714A JPH0517367A (ja) 1991-07-08 1991-07-08 骨粗鬆症治療剤
PCT/JP1992/000874 WO1993000921A1 (en) 1991-07-08 1992-07-07 Remedy for osteoporosis
CA002090453A CA2090453A1 (en) 1991-07-08 1992-07-07 Remedy for osteoporosis
EP92914092A EP0547234A1 (en) 1991-07-08 1992-07-07 Remedy for osteoporosis
KR1019930700665A KR930702016A (ko) 1991-07-08 1992-07-07 골다공증 치료제

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3192714A JPH0517367A (ja) 1991-07-08 1991-07-08 骨粗鬆症治療剤

Publications (1)

Publication Number Publication Date
JPH0517367A true JPH0517367A (ja) 1993-01-26

Family

ID=16295841

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3192714A Pending JPH0517367A (ja) 1991-07-08 1991-07-08 骨粗鬆症治療剤

Country Status (5)

Country Link
EP (1) EP0547234A1 (enExample)
JP (1) JPH0517367A (enExample)
KR (1) KR930702016A (enExample)
CA (1) CA2090453A1 (enExample)
WO (1) WO1993000921A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003043651A1 (ja) * 2001-11-19 2005-03-10 協和醗酵工業株式会社 多分化能幹細胞を組織から末梢血へ動員する薬剤

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
BRPI0909044B8 (pt) * 2008-03-14 2021-05-25 Transgene Sa anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638204B2 (en) * 1987-11-12 1993-06-24 Schering Corporation Acceleration of bone formation with gm-csf
JPH022391A (ja) * 1988-02-08 1990-01-08 Otsuka Pharmaceut Co Ltd ヒトｍ―ｃｓｆ及びその製造法
DE69022606T2 (de) * 1989-02-28 1996-05-02 Morinaga Milk Industry Co Ltd Menschlichen Monozyt-Makrophagen-Koloniestimulierungsfaktor enthaltende Zusammensetzung.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003043651A1 (ja) * 2001-11-19 2005-03-10 協和醗酵工業株式会社 多分化能幹細胞を組織から末梢血へ動員する薬剤

Also Published As

Publication number Publication date
WO1993000921A1 (en) 1993-01-21
KR930702016A (ko) 1993-09-08
EP0547234A1 (en) 1993-06-23
EP0547234A4 (enExample) 1994-02-09
CA2090453A1 (en) 1993-01-09

Similar Documents

Publication Publication Date Title
Grecomoro et al. Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoarthritis of the knee: a preliminary open study
EP1369119B1 (en) Il-12 expression controlling agents
JPH0222229A (ja) 神経細胞及び神経繊維の疾患もしくは傷害の治療に用いる組み合わせ調合剤
JP2000514091A (ja) 心筋症の処置
KR20030034177A (ko) 허혈성 질환 치료제
US20140363394A1 (en) Formulation having mobilizing activity
JP3771280B2 (ja) オステオポローシスの治療方法およびそのための組成物
CA2142455A1 (en) Method for systemic treatment of catabolic conditions and systemic tissue injury
JP2934023B2 (ja) コルチコステロイド治療組成物
JP4480799B2 (ja) 非バイパス侵襲性介入の結果として起こる介入を伴う狭窄症の予防法
JPH0517367A (ja) 骨粗鬆症治療剤
JPH01151514A (ja) 神経疾患治療・予防剤
HU207229B (en) Process for producing pharmaceutical compositions containing gm-csf for treating leukocyte disfunction
EP4322942A1 (en) Combination comprising everolimus and amcenestrant
JP4652689B2 (ja) 骨再生を促進するカルモジュリンの使用
US5854271A (en) Effective method for the amelioration and prevention of tissue and cellular damage
RU2569754C2 (ru) Профилактическое средство, и/или терапевтическое средство, и/или средство, подавляющее ухудшение при деформирующем артрите у человека
JP3916563B2 (ja) Ｐ物質の投与を含む治療方法
CN104587470A (zh) 一种促进骨质疏松性骨折术后骨愈合的药物组合物及其应用
JPH0565492B2 (enExample)
EP4392053A1 (en) Compositions and methods for treatment of bone-related disease or disorder
WO2022077823A1 (zh) 甲氧喹酸在制备用于治疗和/或预防以t-型钙通道为治疗靶点的疾病的药物中的应用
RU2827073C1 (ru) Средство для лечения артрологических заболеваний в лиофилизированной форме для инъекций
JP2759050B2 (ja) 突発性難聴治療用医薬組成物
RU2841157C1 (ru) Применение коллагенполивинилпирролидона при воспалении лёгких и фиброзе у пациентов, инфицированных вирусом sars-cov2 (covid-19)